The treatment of limb soft tissue sarcoma with TNF-alfa and pegylated liposomal doxorubicin (PLD): Phase I-II study
| Autor: | C Sofra, R. Pasqualoni, G. Citro, Pasquale Perri, P. Di Angelo, S. Di Filippo, S. Disegni, F. Di Filippo, M. Anza, R. Garinei |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Cancer Research
Isolation perfusion medicine.medical_specialty Muscle biopsy medicine.diagnostic_test business.industry Soft tissue sarcoma Urology medicine.disease Limb Salvage Procedure Pegylated Liposomal Doxorubicin Surgery Oncology Toxicity medicine Tumor necrosis factor alpha Doxorubicin business medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 26:10583-10583 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2008.26.15_suppl.10583 |
| Popis: | 10583 Background: Hyperthermic isolation perfusion (HILP) has been employed for STS as limb salvage procedure. Fifty-eight patients affected with unresectable STS have been treated with doxorubicin and 1 mg of TNF-alfa. The CR and PR were 34% and 48% respectively, with a limb salvage rate of 84%. Unfortunately, the limb toxicity was quite high, therefore we decided to employ PLD. Methods: Fourteen patients have been treated with escalating dose of liposomal doxorubicin, starting from 10 mg/L of limb volume up to 18 mg/L, at mean muscle temperature of 41.5C. During HILP blood samples were taken from both systemic and perfusional circulation at 10 minutes intervals. At the end of HILP a tumor and muscle biopsy was carried out in order to evaluate the doxorubicin concentration. A total of 18 STS patients have been treated with PLD. All the patients were monitored in terms of grade of limb toxicity (Wieberdink classification) and systemic toxicity (WHO classification). Eleven patients have been later treated ... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|